Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Crinetics Pharmaceuticals (CRNX) Receivables - Other (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Receivables - Other data on record, last reported at $7.8 million in Q4 2025.

  • For Q4 2025, Receivables - Other fell 6.64% year-over-year to $7.8 million; the TTM value through Dec 2025 reached $7.8 million, down 6.64%, while the annual FY2025 figure was $7.8 million, 6.64% down from the prior year.
  • Receivables - Other reached $7.8 million in Q4 2025 per CRNX's latest filing, up from $6.3 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $8.4 million in Q2 2025 and bottomed at $85000.0 in Q1 2021.
  • Average Receivables - Other over 5 years is $3.1 million, with a median of $2.0 million recorded in 2022.
  • Peak YoY movement for Receivables - Other: plummeted 38.85% in 2021, then surged 1529.07% in 2022.
  • A 5-year view of Receivables - Other shows it stood at $499000.0 in 2021, then soared by 171.14% to $1.4 million in 2022, then soared by 125.5% to $3.1 million in 2023, then skyrocketed by 172.37% to $8.3 million in 2024, then dropped by 6.64% to $7.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Other were $7.8 million in Q4 2025, $6.3 million in Q3 2025, and $8.4 million in Q2 2025.